We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Bacterial Infection Identified as Cause of Overactive Bladder Syndrome

By LabMedica International staff writers
Posted on 28 Jul 2016
Overactive Bladder (OAB) is currently characterized by symptoms of urgency, with or without urgency incontinence, with increased frequency, and nocturia, and in some cases pain, in the absence of urinary tract infection (UTI) or other defined underlying pathology.

The exclusion of infection is determined by failure to isolate more than 105 colony forming units (CFU)/mL of a single species of bacteria from culture of a midstream urine (MSU) specimen and negative leukocyte esterase and/or nitrate urinalysis by dipstick.

Scientists at the University of Kent (Chatham, UK) obtained bladder biopsies from local hospitals, and a catheter specimen of urine (CSU) was obtained from female patients and a MSU from male patients and non-OAB controls. More...
All urine samples obtained were sent for conventional urinalysis and bacteria culture at the time of collection, if a UTI was subsequently identified the sample was retrospectively removed from the study.

The bladder biopsies were sectioned and stained and the morphological characteristics of the tissue evaluated. A DM4000B upright light microscope (Leica, Wetlar, Germany) was used to image the sections. A Luciferin Luciferase Adenosine triphosphate (ATP) Bioluminiscence Assay Kit was used to quantify ATP release from intact, live, bladder urothelium. ATP-evoked luminescence was quantified using a Synergy 2 luminometer (BioTek, Winooski, USA). The scientists also performed biopsy vesicle staining, biopsy ribonucleic acid (RNA) extraction and polymerase chain reactions, urine sediment immunofluorescence and urine nucleotide and nucleoside quantification.

The team found that some OAB patients had a low-grade inflammation, which is missed by conventional tests. This low-grade inflammation may ultimately result in increased sensory nerve excitation and the symptoms of OAB. They also found that in these patients the low-grade inflammation is associated with bacteria living inside the bladder wall. This was an observational study which means that no conclusions can be drawn about cause and effect. However, the findings may prompt the clinical re-classification of OAB and inform future therapeutic strategies. These might include protracted treatment with antibiotics to alleviate the symptoms of OAB in some individuals. The study was published on June 29, 2016, in the American Journal of Physiology.

Related Links:
University of Kent
Leica
BioTek

New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The addition of Biocare’s complementary IHC antibody, reagent and instrument portfolio enhances Agilent’s immunohistochemistry offering (Photo courtesy of Biocare Medical)

Agilent Technologies Acquires Pathology Diagnostics Company Biocare Medical

Agilent Technologies (Santa Clara, CA, USA) has entered into a definitive agreement to acquire Biocare Medical (Pacheco, CA, USA), expanding its pathology portfolio through the addition of highly complementary... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.